Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience

被引：0
|
作者：
Leibowitz-Amit, Raya
Atenafu, Eshetu G.
Seah, Jo-An
Templeton, Arnoud J.
Vera-Badillo, Francisco Emilio
Solow, Henry L.
Knox, Jennifer J.
Sridhar, Srikala S.
Tannock, Ian
Joshua, Anthony Michael
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.61
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
61
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
    Ochoa de Olza, M.
    Font, A.
    Sala, N.
    Beltran, M.
    Barretina, P.
    Etxaniz, O.
    Indacoechea, A.
    Hernandez, A.
    Navarro, V.
    Germa, J. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
  • [22] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    [J]. ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [23] Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC)
    Gill, David Michael
    Agarwal, Neeraj
    Hahn, Andrew W.
    Johnson, Eric
    Poole, Austin
    Carroll, Emma
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [24] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer
    Mckay, R. R.
    Werner, L.
    Fiorillo, M.
    Nakabayashi, M.
    Kantoff, P. W.
    Taplin, M-E
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) : 398 - 405
  • [25] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    [J]. ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [26] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer
    R R McKay
    L Werner
    M Fiorillo
    M Nakabayashi
    P W Kantoff
    M-E Taplin
    [J]. Prostate Cancer and Prostatic Diseases, 2016, 19 : 398 - 405
  • [27] Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology
    Demirci, Umut
    Oflazoglu, Utku
    Kodaz, Hilmi
    Ciltas, Aydin
    Kefeli, Umut
    Akyol, Murat
    Ozturk, Banu
    Geredell, Caglayan
    Seker, Mehmet Metin
    Clhan, Saner
    Tastekin, Dldem
    Sevinc, Alper
    Akinci, Muhammad Bulent
    Uysal, Mukremin
    Taskoylu, Burcu Yapar
    Duran, Ayse Ocak
    Yazici, Omer Komi
    Karaoglu, Aziz
    Benekli, Mustafa
    Buyukberber, Suleyman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Dose intensity of abiraterone acetate and administration of post-abiraterone chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) - a real world analysis
    Sonpavde, G.
    Tangirala, K.
    Mehta, J.
    Sung, J.
    Nicacio, L.
    Dhawan, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S711 - S712
  • [29] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [30] Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study.
    Ryan, C. J.
    Harzstark, A. L.
    Lin, A. M.
    Fong, L.
    Grycz, K.
    Szmulewitz, R. Z.
    Weinberg, V. K.
    Molina, A.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345